Select Your Region
Global
Screening Study for Participants With Malignant Tumors
- Cancer
- Solid Tumors
Please note that the recruitment status of the trial at your site may differ.
Trial Status:
Recruiting
This trial runs in
Cities
- Ankara
- Auckland
- Austin
- Beograd
- Blacksburg
- Bogotá
- Bunkyo City
- chang-wat-nonthaburi
- Cheongju-si
- Daegu
- Erzurum
- Fukuoka
- Gwangju
- Himeji
- Hirosaki
- Hong Kong Island
- İstanbul
- Kagoshima
- Kashihara
- Knoxville
- Kobe
- Koto City
- Kragujevac
- Krung Thep Maha Nakhon
- Kumamoto
- Kurashiki
- Kurume
- London
- Longmont
- Manchester
- Matsuyama
- Melbourne
- Memphis
- Minas Gerais
- Nagaizumi
- Nagoya
- New Taipei City
- Niigata
- Okayama
- Osaka
- Osakasayama
- Pittsburgh
- Portland
- Providencia
- Rio Grande do Sul
- Sakai
- Samsun
- San Antonio
- San Diego
- San José
- Sendai
- Seongnam-si
- Seoul
- Singapore
- Sremska Kamenica
- St Leonards
- Taichung City
- Tainan City
- Taipei City
- tambon-kho-hong
- Taoyuan City
- Temuco
- Toronto
- Tucson
- Tyler
- Ube
- Vancouver
- Westmead
- Yokohama
- Yonago
Trial Identifier:
NCT05419375 BX43361
Trial Summary
The study objective is to determine the biomarker status of a participant's tumor tissue and use that status to determine eligibility for a linked Roche clinical trial.
Hoffmann-La Roche
Sponsor
Phase 2
Phase
NCT05419375,BX43361
Trial Identifier
Screening platform
Treatments
Solid Tumors
Condition
Official Title
Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors
Eligibility Criteria
All
Gender
≥18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
General Inclusion Criteria:
- Confirmed availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen meeting criteria defined in the protocol
- Considered by principal investigator (PI) to be a candidate for a linked clinical trial with an investigational medicinal product, and that the participant has the awareness and willingness to participate in said trial
Inclusion Criteria for Participants with Stage III NSCLC
- Locally advanced, unresectable Stage III NSCLC of either squamous or non-squamous histology based on 8th edition of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) cancer staging system
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Exclusion Criteria
General Exclusion Criteria:
- History of malignancy other than NSCLC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death
- Any condition that may affect the interpretation of study results
- Significant liver or cardiovascular disease
- Prior allogenic stem-cell or solid-organ transplantation
For the latest version of this information please go to www.forpatients.roche.com